文献速递糖尿病

2型糖尿病患者心血管结局试验中的复合主要终点:不稳定型心绞痛应纳入主要终点吗?

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
PubMed 文献 · Diabetes Care · 2017-01-01

本文讨论2型糖尿病心血管结局试验(CVOT)中复合主要终点的选择。近期试验显示降糖药对不稳定型心绞痛住院影响似乎很小,纳入该组分可能使风险比趋向无效值,在非劣效试验中尤其成问题。作者认为三成分主要不良心血管事件(3P-MACE)在统计效率、操作复杂性、诊断精确性、临床重要性和捕捉治疗效应之间可能比四成分(4P-MACE)更平衡,但无某一终点可视为所有降糖药CVOT的金标准。

要点

  • 复合终点可增加事件数从而提高统计效能与精确度,是CVOT的实用需要。
  • 近期CVOT显示降糖药对不稳定型心绞痛住院似乎影响很小,纳入后可能使风险比趋向无效值。
  • 3P-MACE在统计效率、操作复杂性、诊断精确性、临床重要性和捕捉治疗效应之间可能比4P-MACE更平衡。

核心结论

  • 3P-MACE在统计效率、操作复杂性、各组分诊断精确性(因而临床相关性)、临床重要性和充分捕捉干预潜在治疗效应之间可能比4P-MACE更平衡;但不同药物对心血管结局的机制影响可能不同,无某一单独或复合终点可视为所有降糖药CVOT的金标准。

研究设计与样本

  • 本文为针对2型糖尿病患者心血管结局试验中复合主要终点选择的论述性文章,未报告系统检索范围或样本量。

主要发现

  • 历史上糖尿病试验的复合心血管终点包含较多组分,而近期CVOT几乎只使用心血管死亡、非致死性心肌梗死和非致死性卒中的三成分复合终点(3P-MACE),或在此基础上加入不稳定型心绞痛住院(4P-MACE)。
  • 纳入不稳定型心绞痛住院增加可分析的事件数,但缺点包括该事件判定存在临床主观性,且其预后相关性低于心血管死亡、心肌梗死或卒中。
  • 近期CVOT结果提示降糖药对不稳定型心绞痛住院似乎影响很小,纳入后可能使风险比趋向无效值,在以证明非劣效为目的的试验中尤其成问题。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Reductions in cardiovascular (CV) outcomes in recently reported trials, along with the recent approval by the U.S. Food and Drug Administration of an additional indication for empagliflozin to reduce the risk of CV death in type 2 diabetes patients with evidence of CV disease, have renewed interest in CV outcome trials (CVOTs) of glucose-lowering drugs. Composite end points are a pragmatic necessity in CVOTs to ensure that sample size and duration of follow-up remain reasonable. Combining clinical outcomes into a composite end point increases the numbers of events ascertained and thus statistical power and precision. Historically, composite CV end points in diabetes trials have included a larger number of components, while more recent CVOTs almost exclusively use a composite of CV death, nonfatal myocardial infarction (MI), and nonfatal stroke-the so-called three-point major adverse CV event (3P-MACE) composite-or add hospitalization for unstable angina (HUA) to these three outcomes (4P-MACE). The inclusion of HUA increases the number of events for analysis, but noteworthy disadvantages include clinical subjectivity in ascertainment of HUA and its lower prognostic relevance compared with CV death, MI, or stroke. Furthermore, results from recent CVOTs indicate that glucose-lowering agents seem to have minimal impact on HUA. Its inclusion therefore potentially favors a shift of the hazard ratio (HR) toward the null, which is especially problematic in trials designed to demonstrate noninferiority. The primary outcome of 3P-MACE may offer a better balance than 4P-MACE between statistical efficiency, operational complexity, the likelihood of diagnostic precision (and therefore clinical relevance) for each of the component outcomes, clinical importance, and the aim to adequately capture any potential treatment effect of the intervention. Nevertheless, as individual medications may mechanistically differ in their impact on CV outcomes, no particular individual or composite end point can be seen as a "gold standard" for CVOTs of all glucose-lowering drugs.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Marx N, McGuire DK, Perkovic V, et al. Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point? Diabetes Care. 2017. PMID: 28830955. doi:10.2337/dc17-0068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。